A Phase 3 interventional study of Elranatamab and Lenalidomide in Multiple Myeloma, sponsored by Pfizer. Active, not recruiting at 209 sites in 27 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-16.
Sponsored by Pfizer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies testing elranatamab in Multiple Myeloma — 21 open to participants now, 25 under way, 5 of them phase 3. elranatamab · Multiple Myeloma.
Among the 31 studies testing elranatamab in Multiple Myeloma, this one is the 3rd largest by enrollment, is one of 2 that started in 2022, is one of 5 in phase 3, reaches primary completion later than 8 of the 24 other live ones, and was the 8th registered.
3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.
Browse Multiple Myeloma studies →21 of the 31 studies testing elranatamab in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:
SCRI Development Innovations, LLC · Sites in United States
Ages 18+
M.D. Anderson Cancer Center · Sites in United States
Celgene · Sites in United States, Canada, China and 5 more countries
Ages 18+
University of Miami · Sites in United States
Ages 18+
Massachusetts General Hospital · Sites in United States
Ages 18+
By country, each count listing its studies:
elranatamab: first FDA approval 2023 (ELREXFIO), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →
Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 19 · Phase 3 5 · Phase 4 2
First in 2017; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 854 is above the median of 41 across 3,008 interventional studies indexed under Multiple Myeloma.
Median enrollment 75 across the 31 interventional studies. Of the 6 that completed or were terminated, 6 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 31 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
44 studies in Multiple Myeloma by Pfizer: 6 open now, 12 under way, 4 of them phase 3. Of 30 finished, 14 (47%) have results posted.
Among the 44 studies in Multiple Myeloma by Pfizer, this one is the 3rd largest by enrollment of the 31 interventional ones that give a count, is one of 5 that started in 2022, is one of 6 in phase 3, reaches primary completion later than 5 of the 11 other live ones, and was the 26th registered.
Pfizer’s Multiple Myeloma studies by the year they started, since 1999.
7 of the studies testing elranatamab in Multiple Myeloma that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05317416Phase 3PfizerStudy With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant | 2027-08-04 |
| NCT06421675Ontario Clinical Oncology Group (OCOG)Outpatient and Intermittent Dosing of Elranatamab in Relapsed/Refractory Multiple Myeloma | 2026-12 |
| NCT06832865Massachusetts General HospitalELISA in Relapsed/Refractory MM | 2026-12-01 |
| NCT06015542Thomas LundSelf-administration of Subcutaneous Elranatamab in the Patients' Homes. | 2026-12-01 |
| NCT06988488CelgeneA Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma | 2027-05-31 |
Add all 7 to your calendar (.ics) → With an account.
Among the 31 studies testing elranatamab in Multiple Myeloma, from their registry updates:
Among Pfizer’s 44 in Multiple Myeloma:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate whether elranatamab monotherapy can provide clinical benefit compared to lenalidomide monotherapy (control) in participants with newly diagnosed multiple myeloma after undergoing autologous stem cell transplant. In Part 1 and Part 2 of the study, participants in the study will either receive elranatamab (arm A and C) as an injection under the skin at the study clinic or lenalidomide orally once daily at home (arm B). Participation in the study will be approximately five years
Elranatamab is a bispecific antibody: binding of elranatamab to CD3-expressing T-cells and BCMA-expressing multiple myeloma cells causes targeted T-cell-mediated cytotoxicity.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Elranatamab
Drug: Elranatamab
Lenalidomide
Drug: Lenalidomide
Lenalidomide
Drug: Lenalidomide
Elranatamab
Drug: Elranatamab
BCMA-CD3 bispecific antibody
Immunomodulatory drug
Immunomodulatory drug
BCMA-CD3 bispecific antibody
Progression Free Survival
Progression Free Survival assessed by Blinded Independent Central review per IMWG response criteria
Time frame: Assessed for up to approximately 5 years
Minimal residual disease Negative rate
per IMWG as assessed via next generation sequencing (NGS)
Time frame: 12 months after randomization
Progression Free Survival by BICR per IMWG in IMWG 2025 high-risk participants
Progression Free Survival by BICR per IMWG in IMWG 2025 high-risk participants
Time frame: Assessed up to approximately 5 years
PFS by BICR per IMWG in IMWG 2025 standard-risk participant
PFS by BICR per IMWG in IMWG 2025 standard-risk participant
Time frame: Assessed up to approximately 5 years
Overall Survival
Defined as the time from randomization until death due to any cause
Time frame: Assessed for up to approximately 5 years
MRD-negative rate per IMWG 2025
Assessed via NGS in IMWG 2025 subgroups
Time frame: 12 months after randomization
Sustained MRD negative rate
Sustained Minimal Residual Disease negative rate per IMWG criteria as assessed via Next Generation Sequencing
Time frame: 24 months after randomization
Progression Free Survival
Progression Free Survival by investigator per IMWG response criteria
Time frame: Assessed for up to approximately 5 years
Overall minimal residual disease negative rate
Minimal residual disease negative rate per IMWG criteria
Time frame: Assessed for up to approximately 5 years
Duration of minimal residual disease negativity
Minimal residual disease negativity per IMWG criteria
Time frame: Assessed for up to approximately 5 years
Sustained minimal residual disease negativity rate
Minimal residual disease negativity per IMWG criteria that has lasted a minimum of 12 months
Time frame: Assessed for up to approximately 5 years
Complete response rate
Complete response rate by blinded independent central review and by investigator per IMWG criteria
Time frame: Assessed for up to approximately 5 years
Duration of complete response
Duration of complete response by blinded independent central review and by investigator per IMWG criteria
Time frame: Assessed for up to approximately 5 years
Progression Free Survival 2
Progression Free Survival to the date of second objective disease progression by investigator per IMWG response criteria
Time frame: Assessed for up to approximately 5 years
Frequency of adverse events
Adverse event as characterized by type, frequency, severity per the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5, seriousness and relationship to the study intervention
Time frame: Up to 90 days after last dose
Severity of Cytokine Release Syndrome and Immune effector Cell Associated Neurotoxicity syndrome
Cytokine Release Syndrome and Immune effector Cell Associated Neurotoxicity syndrome severity assessed per ASH-ASTCT criteria
Time frame: Assessed for up to approximately 5 years
Pre-dose concentrations of elranatamab
Pharmacokinetics of elranatamab (trough concentrations of elranatamab)
Time frame: Assessed for up to approximately 5 years
Post-dose concentrations of elranatamab
Pharmacokinetics of elranatamab (Post-dose serum concentrations of elranatamab)"
Time frame: Assessed for up to approximately 5 years
Incidence and titers of Anti-Drug Antibody and Neutralizing Antibody against elranatamab
Immunogenicity of elranatamab
Time frame: Assessed for up to approximately 5 years
Health-related quality of life by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30
Higher scores on the functional scales represent higher levels of functioning. Higher scores on the global health status/quality of life scale represent higher health status/quality of life. Higher scores on symptom scales/items represent a greater presence of symptoms
Time frame: Assessed for up to approximately 5 years
Health-related quality of life by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Myeloma 20
Higher scores on the functioning subscales (body image, future perspective) represent higher levels of functioning, whereas higher scores on the symptom subscales (disease symptoms, side effects) represent a greater presence of symptoms
Time frame: Assessed for up to approximately 5 years
Showing the first 100 of 209 sites across 27 countries. Choose a country and city above to see the rest.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Started Mar 2022 (actual). Primary completion is estimated for Aug 2027, 64 months after the start.
Of 107 industry-sponsored phase 3 interventional studies under Multiple Myeloma, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 66. This study's planned 64 months is above that.
Counting every sponsor, half of 179 studies reached it within 55 months; a quarter within 34 and three quarters within 95.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Elranatamab